Explore

Trendline Trendline
Biogen Advances Alzheimer's Drug Diranersen to Phase 3 Despite Phase 2 Challenges

Biogen Advances Alzheimer's Drug Diranersen to Phase 3 Despite Phase 2 Challenges

Biogen Advances Alzheimer's Drug Diranersen to Phase 3 Despite Phase 2 Challenges
Trendline Trendline
Biogen Advances Tau Alzheimer's Therapy to Phase 3 Amid Cautious Optimism

Biogen Advances Tau Alzheimer's Therapy to Phase 3 Amid Cautious Optimism

Biogen Advances Tau Alzheimer's Therapy to Phase 3 Amid Cautious Optimism
Trendline Trendline
Biogen Advances Alzheimer's Drug Diranersen Despite Phase 2 Trial Setback

Biogen Advances Alzheimer's Drug Diranersen Despite Phase 2 Trial Setback

Biogen Advances Alzheimer's Drug Diranersen Despite Phase 2 Trial Setback
Trendline Trendline
Biogen Advances Tau Alzheimer's Therapy to Phase 3 Despite Mid-Stage Setback

Biogen Advances Tau Alzheimer's Therapy to Phase 3 Despite Mid-Stage Setback

Biogen Advances Tau Alzheimer's Therapy to Phase 3 Despite Mid-Stage Setback
Trendline Trendline
Biogen Advances Tau-Targeting Alzheimer's Therapy to Phase 3 Despite Mid-Stage Trial Challenges

Biogen Advances Tau-Targeting Alzheimer's Therapy to Phase 3 Despite Mid-Stage Trial Challenges

Biogen Advances Tau-Targeting Alzheimer's Therapy to Phase 3 Despite Mid-Stage Trial Challenges
Trendline Trendline
Fosun Pharma and AriBio Sign Agreement for Alzheimer's Drug Development

Fosun Pharma and AriBio Sign Agreement for Alzheimer's Drug Development

Fosun Pharma and AriBio Sign Agreement for Alzheimer's Drug Development
Trendline Trendline
MEDIPOST's CARTISTEM Achieves Key Milestones in Japan Phase 3 Trial

MEDIPOST's CARTISTEM Achieves Key Milestones in Japan Phase 3 Trial

MEDIPOST's CARTISTEM Achieves Key Milestones in Japan Phase 3 Trial
Rapid Read Rapid Read
PureTech to Present Deupirfenidone as Potential New Standard for IPF Treatment

PureTech to Present Deupirfenidone as Potential New Standard for IPF Treatment

PureTech Health is set to present its deupirfenidone (LYT-100) program at the American Thoracic Society International Conference. Deupirfenidone is being developed as a potential new standard of care for idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. The presentations will highlight the drug's differentiated approach and its potential to improve upon current treatments. The Phase 3 SURPASS-IPF trial aims to demonstrate deupirfenidone's superiority over existing therapies, addressing the unmet need for more effective IPF treatments. The drug has shown promise in stabilizing lung function with a favorable safety profile in earlier trials.
Trendline Trendline
Perspective Therapeutics Advances VMT-α-NET with High Efficacy in Clinical Trials

Perspective Therapeutics Advances VMT-α-NET with High Efficacy in Clinical Trials

Perspective Therapeutics Advances VMT-α-NET with High Efficacy in Clinical Trials
Trendline Trendline
Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaborations

Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaborations

Agenus Advances BOT+BAL Immunotherapy with Phase 3 Trial and Strategic Collaborations
Trendline Trendline
Novo Nordisk's microRNA Drug Fails to Show Benefit in Heart Failure Trial

Novo Nordisk's microRNA Drug Fails to Show Benefit in Heart Failure Trial

Novo Nordisk's microRNA Drug Fails to Show Benefit in Heart Failure Trial
Trendline Trendline
Altesa BioSciences' Vapendavir Shows Promise Against All Rhinovirus Species

Altesa BioSciences' Vapendavir Shows Promise Against All Rhinovirus Species

Altesa BioSciences' Vapendavir Shows Promise Against All Rhinovirus Species